Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Techne (TECH) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Bio-Techne (TECH) over the last 17 years, with Q4 2025 value amounting to $5.9 million.

  • Bio-Techne's Capital Expenditures fell 1319.45% to $5.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $26.3 million, marking a year-over-year decrease of 4783.79%. This contributed to the annual value of $31.0 million for FY2025, which is 5068.79% down from last year.
  • As of Q4 2025, Bio-Techne's Capital Expenditures stood at $5.9 million, which was down 1319.45% from $5.4 million recorded in Q3 2025.
  • In the past 5 years, Bio-Techne's Capital Expenditures registered a high of $18.0 million during Q2 2024, and its lowest value of $4.9 million during Q2 2025.
  • Moreover, its 5-year median value for Capital Expenditures was $10.4 million (2021), whereas its average is $10.5 million.
  • In the last 5 years, Bio-Techne's Capital Expenditures surged by 14331.31% in 2023 and then plummeted by 7280.31% in 2025.
  • Bio-Techne's Capital Expenditures (Quarter) stood at $10.2 million in 2021, then plummeted by 39.92% to $6.1 million in 2022, then soared by 143.31% to $14.9 million in 2023, then plummeted by 54.11% to $6.8 million in 2024, then dropped by 13.19% to $5.9 million in 2025.
  • Its Capital Expenditures stands at $5.9 million for Q4 2025, versus $5.4 million for Q3 2025 and $4.9 million for Q2 2025.